Navigation Links
Biotech Industry Veteran Joseph Bolen Joins Moderna Therapeutics to be President of Research and Development
Date:7/31/2013

CAMBRIDGE, Mass., July 31, 2013 /PRNewswire/ -- Moderna Therapeutics, the pioneering company developing messenger RNA therapeutics™, a revolutionary new treatment modality to enable the in vivo production of therapeutic proteins, announced today that Joseph Bolen, Ph.D., joined Moderna as its president of research and development (R&D).

Dr. Bolen, the chief scientific officer and global head of oncology research at Millennium: The Takeda Oncology Company has served in senior leadership positions at Millennium since 1999. As the Millennium CSO and global head of research, Dr. Bolen has a proven track record of leading a large and multi-faceted international R&D organization while fostering a culture of scientific innovation within a global commercial-stage company. He has more than 30 years of industry and research experience and has been at the forefront of cancer and immunology research since starting his career as a scientist at the National Institutes of Health (NIH).

"Messenger RNA therapeutics™ promises to vastly expand the number of diseases we can treat and usher in an entirely new era of drug discovery and development," said Stephane Bancel, president and founding CEO of Moderna. "To advance our internal programs in genetic rare diseases and oncology and support partners in many additional therapeutic areas, we are building an R&D organization that is second to none. Joe's deep scientific knowledge and strong vision will help us to create a culture and a structure that can move rapidly to turn scientific innovation into therapies that make a true difference for patients. I am very happy and honored to partner with such an accomplished and thoughtful scientific leader and drug hunter as Joe to build a very special company for patients and our team."

Dr. Bolen will oversee all aspects of R&D at Moderna, including dis
'/>"/>

SOURCE Moderna Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Biotechnology (BSMA) Conference For Supply Chain Professionals Returns To Foster City, October 8-9, 2013
2. Plant Biotechnology Companies Begin New Conversation about GMOs and How our Food is Grown
3. Nobel Laureate Dr. Oliver Smithies to Deliver Plenary Session at ISPE Biotechnology Symposium
4. Biotech Investment Group Launches Formex, LLC
5. BioTech Companies in the News - Alliqua, Transition Therapeutics, Organovo, MiMedx Group, Keryx Biopharmaceuticals
6. TriMix for Travel Now Available at KRS Global Biotechnology
7. Chief Medical Officer Summit for Biotechs Goes West
8. PROLOR Biotech To Present New Data On Its Long-Acting Human Growth Hormone And Long-Acting Oxyntomodulin At ENDO 2013
9. Zacks Investment Ideas feature highlights: Market Vectors Biotech ETF, iShares Nasdaq Biotechnology ETF, Regeneron, Celgene and First Trust Amex Biotechnology Index Fund
10. MedReps.com Report Shows Biotech Workers Earn the Most in Medical Sales
11. Biotechnology Master’s at UMBC Shady Grove - Virtual Info Session to Be Held on June 26
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2015)... IL (PRWEB) May 30, 2015 ... cutting-edge, novel research for bile duct cancer, announced ... launched Research Fellowship Program. , The ... outstanding scientists throughout the country to raise awareness ... funding will support research that opens new pathways ...
(Date:5/30/2015)... CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and ... BAX ) today announced data from PERSIST-1 – a ... treatment of myelofibrosis – in a late-breaking oral session ... Society of Clinical Oncology (ASCO), May 29-June 2, 2015 ... an investigational oral multikinase inhibitor with specificity for JAK2 ...
(Date:5/30/2015)... RARITAN, N.J. , May 30, ... two-part, single-arm Phase 2 MMY2002 (SIRIUS) trial show ... anti-CD38 monoclonal antibody – achieved an overall response ... as assessed by an independent review committee, in ... was consistent among the pre-specified subgroups based on ...
(Date:5/30/2015)... 2015  Caris Life Sciences® today announced the ... researchers identified biomarker changes, including key driver mutations, ... changes in response to therapy as the disease ... subset of a larger study analyzing 1,245 glioma ... These data utilizing Caris Molecular Intelligence®, the company,s ...
Breaking Biology Technology:The Cholangiocarcinoma Foundation Awards $260,000 in Research Grants 2The Cholangiocarcinoma Foundation Awards $260,000 in Research Grants 3Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 2Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 3Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 4Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 5Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 6Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 7Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 8Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 9Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 10Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 2Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 3Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 4Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 5Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 6Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 7Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 2Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 3Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 4
... dream of competing together to race the fastest cars they ... group of 20 engineers, scientists and technicians from Ohio State ... is to win the $1 million dollar grand prize awarded ... , ,The Defense Advanced Research Projects Agency (DARPA) has ...
... Wis. -- Fiserv Inc., a provider ... Management, a portfolio management and investment accounting solution. ... trade execution, accounting, international settlement support and regulatory ... handle several accounting bases and closing dates and ...
... and community development specialist, presented a hopeful outlook for ... on Economic Development . Abstaining from morbid statistics and ... businesses in Wisconsin. , ,Wisconsin manufacturing suffered very little ... He cited that Wisconsin saw only a 9.1 percent ...
Cached Biology Technology:Oshkosh Truck Teams with OSU to Compete in DARPA Million Dollar Tech Derby 2Oshkosh Truck Teams with OSU to Compete in DARPA Million Dollar Tech Derby 3Optimistic Outlook For Manufacturing 2
(Date:5/29/2015)... , May 28, 2015 Research ... addition of the "Facial Recognition Market by ... - Global Forecast to 2020" report to ... have seen facial recognition technology become more efficient ... to gain traction and investment from the commercial ...
(Date:5/28/2015)... GLEN ALLEN, Va. , May 28, 2015 ... announced the release of a new report titled ... self-healing materials (reversible polymers, inorganic capsule and vascular ... self-healing coatings) will grow to around $2.7 billion ... latest deliverable from n-tech,s extensive coverage of smart ...
(Date:5/27/2015)... 27, 2015   Codonics (codonics.com), ... and image documentation solutions and Omnicell ... automation solutions, is pleased to announce their ... Safe Label System® (SLS), an award-winning FDA ... the Omnicell Anesthesia Workstation, helps prevent medication ...
Breaking Biology News(10 mins):Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 3Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4
... are small, lungless amphibians that live in moist, forest ... serve as vital links in forest food chains; their ... predict the health of forest ecosystems. Now, researchers at ... size reflects forest habitat quality and can predict how ...
... intracellular particle tracking (simultaneous tracking of the motions ... and even individual molecules), that is an important ... search for appropriate medicines against certain diseases (including ... winner. Techniques proposed by all the participants, ...
... levels of air pollutants were nearly three times as likely ... of pollution exposure, report researchers at Columbia University Medical Center ... both increased dramatically in the past 30 years. The percentage ... in 1980 to 20% in 2008. Childhood asthma is up ...
Cached Biology News:Salamanders help predict health of forest ecosystems and inform forest management 29 and 60 ways of particle tracking 29 and 60 ways of particle tracking 3Obese children more susceptible to asthma from air pollution 2
Determin interaction of your protein with Echelons lipids...
Anti-Human Complement Component C4c, IgY fraction (Polyclonal) (chicken IgY)...
... tubes are used to store 2.0 ml ... uniform walls for uniform heat transfer and ... caps. The O-rings are made of polyethylene ... from -55 to 150 degrees C. Supplied ...
... protein A media yield highly purified ... to analysis of other immunoglobulin classes, ... purification. Protein A binds to the ... from mammalian species. This ready-to-use, bottled ...
Biology Products: